Bavarian Nordic: We can adapt our vaccine if necessary
If it needs to, Bavarian Nordic will be able to keep pace with Moderna and Pfizer/Biontech and change its Covid-19 vaccine so it works against the Omicron variant.
by marketwire, translated by catherine brett
It is not yet known whether the current Covid-19 vaccines are effective against the Omicron variant of the coronavirus, or whether they will need to be adapted, says Rolf Sass Sørensen, vice president of investor relations at Bavarian Nordic, to MarketWire.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
